B
LXEO icon

Braidwell’s Lexeo Therapeutics LXEO Stock Holding History

Braidwell’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-728,777
Closed -$6.59M – 85
2024
Q3 		$6.59M Sell
728,777
-653,704
-47% -$7.8M 0.19% 70
2024
Q2 		$22.2M Buy
1,382,481
+60,204
+5% +$874K 0.7% 46
2024
Q1 		$20.7M Buy
+1,322,277
New +$20.7M 0.67% 48

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DCP
D1 Capital Partners New York $34.8B AUM 11.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Braidwell's LXEO Position: Q4 2024 in Review

Braidwell sold out of Lexeo Therapeutics (LXEO) in Q4 2024, closing a stake of 728,777 shares — an estimated $6.59M sold.

Braidwell first reported a position in LXEO in Q1 2024 and held it in 3 quarters. The position peaked at $22.2M in Q2 2024. 90 funds tracked by Wall St. Rank hold LXEO as of Q4 2024.

  • Braidwell reported no remaining Lexeo Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Braidwell sold 728,777 Lexeo Therapeutics shares in Q4 2024, an estimated $6.59M.
  • Braidwell first reported a position in Lexeo Therapeutics in Q1 2024 and held it in 3 quarters.
  • Braidwell's Lexeo Therapeutics position peaked at $22.2M in Q2 2024.
  • 90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q4 2024.

Based on Braidwell's 13F filing for Q4 2024, filed 14 Feb 2025.